Thomas Insel will expand Google parent company Alphabet’s medical technology efforts to encompass mental health
By andThomas Insel, a pioneer in the charge to reform psychiatric diagnoses, will step down as director of the US National Institute of Mental Health (NIMH), he announced on September 15.
Insel will take up a job with the Google Life Sciences group at Alphabet, the computer giant's new parent company in Mountain View, California. There, Insel will expand the group’s medical technology efforts—which currently include development of a contact lens that monitors glucose in people with diabetes—to encompass mental health.
Insel arrived at the NIMH in 2002 as a bench scientist who had not focused on clinical research or practice in about 20 years. He had planned to leave after a decade, but two developments enticed him to stay on: in December 2011 the National Institutes of Health (NIH) created a new institute—the National Center for Advancing Translational Sciences—and in 2013 the Obama administration launched , an ambitious endeavour to study the human brain.
“I chose this moment because I wanted to leave at a high point,” he wrote in . “I want to step away at the best of times with all signs pointing to a bright future.”
Looking for the sourceInsel told investigators to embrace studies that crossed or subdivided classical diagnostic categories, in hopes of learning more about the biology underlying the disorders.
The move, announced shortly before a highly publicized release of an updated edition of the , was the most controversial of his tenure, Insel says. “It took a lot of courage,” says Steven Hyman, director of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, and a former NIMH director. “And it was important—it frees investigators from the tyranny of the demonstrably false categories of the .”
Insel continued his push to drill down into the causes of mental-health disorders in 2014, when he without investigating the mechanisms underlying disease. “Patients really need something better,” he says. “They need something that really allows earlier diagnosis and a better outcome.”
Technology companies such as Alphabet could take an important step towards those goals, says Hyman, who has also been in discussions with Google Life Sciences about its plans in mental health. Symptoms of depression, for example, wax and wane daily, on the basis of a 30-minute observation every two weeks. Continuous monitoring of online activity or sleep habits could improve the treatment of depression.
No comments:
Post a Comment